Pharma M&A Booming In First Eight Months Of The Year
This article was originally published in The Pink Sheet Daily
The year 2015 could give 2014 a run for the money in terms of biopharma M&A deal value. From January through August, 18 deals were signed with an upfront value of more than $1bn, representing a total upfront value of $133bn.
You may also be interested in...
The year 2014 was the biggest for pharma M&A in recent history, though it may be remembered equally for sagas and upsets that never materialized into finalized deals. Actavis, in the end, was the most aggressive acquirer, buying Forest and Allergan for a total of $89.3 billion in the two most expensive deals of the year.
Orna is retaining full ownership of its "crown jewel," in situ CAR programs for cancer. CEO Tom Barnes talked to Scrip about the deal and Orna's business strategy.
The pediatric market represents 70%-75% of the market for pneumococcal vaccines; Merck & Co.'s Vaxneuvance was already approved for infants earlier this year.